LIXTE BIOTECHNOLOGY HOLDINGS (LIXT)       0.79  +0.02 (+2.6%)

0.79  +0.02 (+2.6%)

US5393192027 - Common Stock - After market: 0.85 +0.06 (+7.59%)


Fundamental Rating

3

Overall LIXT gets a fundamental rating of 3 out of 10. We evaluated LIXT against 640 industry peers in the Biotechnology industry. While LIXT has a great health rating, but there are worries on its profitability. LIXT has a expensive valuation and it also scores bad on growth

Note: LIXT has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

1

The Piotroski-F score of LIXT is 3.00. This is a low score and indicates issues in the health and profitability of LIXT.

VS Industry

Valuation

Valuation Rating

1

With a price book ratio of 2.05, LIXT is valued correctly.
Compared to an average industry price book ratio of 1.89, LIXT is valued in line with its industry peers.

The Price/Earnings Ratio is negative for LIXT. In the last year negative earnings were reported.
VS Industry

Price/Book (2.05) VS Industry: 47% outperformed.

448.49
0.07

Growth

Growth Rating

0

LIXT shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.88%.


PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -4.88% N/A N/A N/A N/A
RevenueN/A N/A N/A N/A N/A N/A N/A

Health

Health Rating

8

LIXT has a Current Ratio of 16.70. This indicates that LIXT is financially healthy and has no problem in meeting its short term obligations.
LIXT is one of the better placed companies in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 6.21. LIXT has a better rating than 88% of its industry peers.
LIXT has a Quick Ratio of 16.70. This indicates that LIXT is financially healthy and has no problem in meeting its short term obligations.
The Quick Ratio of LIXT is much better than the industry average of 6.11. LIXT has a better rating than 88% of its industry peers.

An Altman-Z score of 8.14 indicates that LIXT is not in any danger for bankruptcy at the moment.
The Altman-Z score of LIXT is much better than the industry average of 0.01. LIXT has a better rating than 82% of its industry peers.
The Debt to Equity ratio of LIXT is in line with the industry averages.
LIXT has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of LIXT.
VS Industry

Debt/Equity (0) VS Industry: 42% outperformed.

15.37
0.00

Quick Ratio (16.7) VS Industry: 88% outperformed.

0.04
84.53

Current Ratio (16.7) VS Industry: 88% outperformed.

0.08
85.09

Altman-Z (8.14) VS Industry: 82% outperformed.

-94.26
670.27

Dividend

Dividend Rating

0

LIXT does not give a dividend.

LIXTE BIOTECHNOLOGY HOLDINGS0.79

NASDAQ:LIXT (2/3/2023, 7:00:03 PM)+0.02 (+2.6%)

After market: 0.85 +0.06 (+7.59%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-22 2022-11-22/bmo Earnings (Next) N/A N/A
Inst Owners 3.9% Inst Owner Change 0%
Ins Owners 1% Ins Owner Change 61.64%
Market Cap 13.15M Analysts N/A
Price Target N/A

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP 0%
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) N/A Avg EPS beat(2) N/A
Min EPS beat(2) N/A Max EPS beat(2) N/A
EPS beat(4) N/A Avg EPS beat(4) N/A
Min EPS beat(4) N/A Max EPS beat(4) N/A
Revenue beat(2) N/A Avg Revenue beat(2) N/A
Min Revenue beat(2) N/A Max Revenue beat(2) N/A
Revenue beat(4) N/A Avg Revenue beat(4) N/A
Min Revenue beat(4) N/A Max Revenue beat(4) N/A
PT rev (1m) N/A PT rev (3m) N/A
EPS NQ rev (1m) N/A EPS NQ rev (3m) N/A
EPS NY rev (1m) N/A EPS NY rev (3m) N/A
Revenue NQ rev (1m) N/A Revenue NQ rev (3m) N/A
Revenue NY rev (1m) N/A Revenue NY rev (3m) N/A

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.05
P/tB 2.05
EV/EBITDA N/A
EPS(TTM) -0.45 EY N/A
EPS(NY) N/A Fwd EY N/A
FCF(TTM) -0.27 FCFY N/A
OCF(TTM) -0.27 OCFY N/A
SpS N/A BVpS 0.39
TBVpS 0.39 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM N/A
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y N/A GM growth 5Y N/A
F-Score 3 Asset Turnover N/A

Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Profit Quality N/A
Current Ratio 16.7
Quick Ratio 16.7
Altman-Z 8.14
F-Score 3 WACC N/A
ROIC/WACC N/A Cap/Depr(3y) N/A
Cap/Depr(5y) N/A Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y -4.88% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 1.56%
EPS Next Y N/A EPS Next 2Y N/A
EPS Next 3Y N/A EPS Next 5Y N/A
Revenue growth 1Y N/A Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
EBIT growth 1Y -19.7% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year N/A
EBIT Next 3Y N/A EBIT Next 5Y N/A
FCF growth 1Y -158.53% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y -158.53%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA